19515-6 |
Levomethamphetamine cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Levomethamphetamine cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19515-6 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
L-methamphet CtO Ur Cfm-mCnc |
|
|
|
Y |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Levo-methamphetamine; L-methamphet; L-methamphetamine; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19516-4 |
Levorphanol |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Levorphanol [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19516-4 |
|
Screen |
|
|
Both |
|
|
|
0 |
Levorphanol Ur Ql Scn |
|
|
|
|
|
Addiction; Dromoran; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Levo-dromoran; Levorphan; Methorphinan; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19518-0 |
Levorphanol cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
Levorphanol cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19518-0 |
|
Screen |
|
|
Observation |
|
|
|
0 |
Levorphanol CtO Ur Scn-mCnc |
|
|
|
Y |
|
CtO; Dromoran; DRUG/TOXICOLOGY; Drugs; Level; Levo-dromoran; Levorphan; Mass concentration; Methorphinan; Point in time; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19519-8 |
Levorphanol cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Levorphanol cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19519-8 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Levorphanol CtO Ur Cfm-mCnc |
|
|
|
Y |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; Dromoran; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Levo-dromoran; Levorphan; Mass concentration; Methorphinan; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
1952-1 |
Beta-2-Microglobulin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Beta-2-Microglobulin [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/L;mcg/mL; ng/mL |
|
|
|
|
|
|
CHEM |
|
1952-1 |
|
|
|
|
Both |
|
|
|
0 |
B2 Microglob SerPl-mCnc |
|
|
|
Y |
|
B; B2 Microglob; b2-M; Chemistry; Hematology; Heme; II; Level; Mass concentration; Microglob; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UniversalLabOrders |
2.73 |
1 |
|
|
|
|
|
|
|
mg/L;ug/mL |
|
|
|
293 |
19520-6 |
LORazepam |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
LORazepam [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19520-6 |
|
Screen |
|
|
Both |
|
|
|
0 |
LORazepam Ur Ql Scn |
|
|
|
|
|
Addiction; Ativan; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19522-2 |
LORazepam cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
LORazepam cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19522-2 |
|
Screen |
|
|
Observation |
|
|
|
0 |
LORazepam CtO Ur Scn-mCnc |
|
|
|
Y |
|
Ativan; CtO; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19523-0 |
LORazepam cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
LORazepam cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19523-0 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
LORazepam CtO Ur Cfm-mCnc |
|
|
|
Y |
|
Ativan; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19524-8 |
Lormetazepam |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Lormetazepam [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19524-8 |
|
Screen |
|
|
Both |
|
|
|
0 |
Lormetazepam Ur Ql Scn |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19525-5 |
Lormetazepam |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Lormetazepam [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19525-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Lormetazepam Ur Ql Cfm |
|
|
|
|
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19526-3 |
Lormetazepam cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
Lormetazepam cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19526-3 |
|
Screen |
|
|
Observation |
|
|
|
0 |
Lormetazepam CtO Ur Scn-mCnc |
|
|
|
Y |
|
CtO; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19527-1 |
Lormetazepam cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Lormetazepam cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19527-1 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Lormetazepam CtO Ur Cfm-mCnc |
|
|
|
Y |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19528-9 |
Lysergate diethylamide |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Lysergate diethylamide [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19528-9 |
|
Screen |
|
|
Both |
|
|
|
0 |
LSD Ur Ql Scn |
|
|
|
|
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; LSD; Lysergic acid; Lysergic acid diethylamide; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
1953-9 |
Beta-2-Microglobulin |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Beta-2-Microglobulin [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/L;mcg/mL; ng/mL |
|
|
|
|
|
|
CHEM |
|
1953-9 |
|
|
|
|
Both |
|
|
|
0 |
B2 Microglob Ur-mCnc |
|
|
|
Y |
|
B; B2 Microglob; b2-M; Chemistry; Hematology; Heme; II; Level; Mass concentration; Microglob; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1 |
|
|
|
|
|
|
|
ug/L;ng/mL |
|
|
|
0 |
19530-5 |
Lysergate diethylamide cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
Lysergate diethylamide cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19530-5 |
|
Screen |
|
|
Observation |
|
|
|
0 |
LSD CtO Ur Scn-mCnc |
|
|
|
Y |
|
CtO; DRUG/TOXICOLOGY; Drugs; Level; LSD; Lysergic acid; Lysergic acid diethylamide; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; UA; UR; Urn |
2.34 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19531-3 |
Lysergate diethylamide cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Lysergate diethylamide cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19531-3 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
LSD CtO Ur Cfm-mCnc |
|
|
|
Y |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; LSD; Lysergic acid; Lysergic acid diethylamide; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.36 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19532-1 |
Meperidine |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Meperidine [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19532-1 |
|
Screen |
|
|
Both |
|
|
|
0 |
Meperidine Ur Ql Scn |
|
|
|
|
|
Addiction; Algil; Alodan; Centralgine; Demerol; Dispadol; Dolantin; Dolosal; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Ordinal; Pethidine; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19534-7 |
Meperidine cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
Meperidine cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19534-7 |
|
Screen |
|
|
Observation |
|
|
|
0 |
Meperidine CtO Ur Scn-mCnc |
|
|
|
Y |
|
Algil; Alodan; Centralgine; CtO; Demerol; Dispadol; Dolantin; Dolosal; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pethidine; Point in time; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19535-4 |
Meperidine cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Meperidine cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19535-4 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Meperidine CtO Ur Cfm-mCnc |
|
|
|
Y |
|
Algil; Alodan; Centralgine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; Demerol; Dispadol; Dolantin; Dolosal; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Pethidine; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19536-2 |
Mephobarbital |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Mephobarbital [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19536-2 |
|
Screen |
|
|
Both |
|
|
|
0 |
Mephobarbital Ur Ql Scn |
|
|
|
|
|
Barbiturate; DRUG/TOXICOLOGY; Drugs; Mebaral; Methylphenobarbital; Ordinal; Phenitone; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19537-0 |
Mephobarbital |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Mephobarbital [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19537-0 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Mephobarbital Ur Ql Cfm |
|
|
|
|
|
Barbiturate; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mebaral; Methylphenobarbital; Ordinal; Phenitone; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19539-6 |
Mephobarbital |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Mephobarbital [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19539-6 |
|
|
|
|
Both |
|
|
|
0 |
Mephobarbital Ur-mCnc |
|
|
|
Y |
|
Barbiturate; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Mebaral; Methylphenobarbital; Phenitone; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
1954-7 |
Beta-N-acetylhexosaminidase |
CCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Beta-N-acetylhexosaminidase [Enzymatic activity/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/hr/mL;nmol/mL/H; units/L |
|
|
|
|
|
|
CHEM |
|
1954-7 |
|
|
|
|
Both |
|
|
|
0 |
B-NAH SerPl-cCnc |
|
|
|
Y |
|
B; B-NAH; Catalytic Concentration; Chemistry; GM2-gangliosidosis; Hex A; Hex B; HEXA; Hexosaminidase; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Sandhoff disease; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tay Sachs Disease |
2.73 |
1 |
|
|
|
|
|
|
|
nmol/h/mL |
|
|
Updated System from Ser to Ser/Plas since this test can be performed on serum or plasma. |
0 |
19540-4 |
Mephobarbital cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
Mephobarbital cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19540-4 |
|
Screen |
|
|
Observation |
|
|
|
0 |
Mephobarbital CtO Ur Scn-mCnc |
|
|
|
Y |
|
Barbiturate; CtO; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Mebaral; Methylphenobarbital; Phenitone; Point in time; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19541-2 |
Mephobarbital cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Mephobarbital cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19541-2 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Mephobarbital CtO Ur Cfm-mCnc |
|
|
|
Y |
|
Barbiturate; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Mebaral; Methylphenobarbital; Phenitone; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |